Your browser doesn't support javascript.
loading
Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort.
Masuda, Norikazu; Ono, Makiko; Mukohara, Toru; Yasojima, Hiroyuki; Shimoi, Tatsunori; Kobayashi, Kokoro; Harano, Kenichi; Mizutani, Makiko; Tanioka, Maki; Takahashi, Shunji; Kogawa, Takahiro; Suzuki, Takuya; Okumura, Shiori; Takase, Takao; Nagai, Reiko; Semba, Taro; Zhao, Zi-Ming; Ren, Min; Yonemori, Kan.
Affiliation
  • Masuda N; Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan. Electronic address: nmasuda@alpha.ocn.ne.jp.
  • Ono M; Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Mukohara T; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Yasojima H; Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
  • Shimoi T; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Kobayashi K; Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Harano K; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Mizutani M; Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
  • Tanioka M; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Takahashi S; Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Kogawa T; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Suzuki T; Japan and Asia Clinical Development Department, Oncology Business Group, Eisai Co., Ltd., Tokyo, Japan.
  • Okumura S; Japan and Asia Clinical Development Department, Oncology Business Group, Eisai Co., Ltd., Tokyo, Japan.
  • Takase T; Clinical Data Science Department, Medicine Development Center, Eisai Co., Ltd., Tokyo, Japan.
  • Nagai R; Clinical Data Science Department, Medicine Development Center, Eisai Co., Ltd., Tokyo, Japan.
  • Semba T; Tsukuba Research Department, Oncology Business Group, Eisai Co., Ltd., Ibaraki, Japan.
  • Zhao ZM; Translational Science, Oncology Business Group, Eisai Inc., Nutley, NJ, USA.
  • Ren M; Biostats, Oncology Business Group, Eisai Inc., Nutley, NJ, USA.
  • Yonemori K; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Eur J Cancer ; 168: 108-118, 2022 06.
Article in En | MEDLINE | ID: mdl-35500404
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Furans / Ketones Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Eur J Cancer Year: 2022 Document type: Article Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Furans / Ketones Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Eur J Cancer Year: 2022 Document type: Article Country of publication: United kingdom